Panbela Therapeutics (PBLA) 10-Q 10 Aug 23 2023 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2023	Aug. 07, 2023
Document Information [Line Items]
Entity Central Index Key	0001029125
Entity Registrant Name	Panbela Therapeutics, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2023
Document Transition Report	false
Entity File Number	001-39468
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	88-2805017
Entity Address, Address Line One	712 Vista Blvd #305
Entity Address, City or Town	Waconia
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55387
City Area Code	952
Local Phone Number	479-1196
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	PBLA
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		2,957,736

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 7,205	$ 1,285
Prepaid expenses and other current assets	3,411	443
Income tax receivable	193	49
Total current assets	10,809	1,777
Other non-current assets	8,742	3,201
Total assets	19,551	4,978
Current liabilities:
Accounts payable	8,440	2,865
Accrued expenses	1,008	2,993
Accrued interest payable	107	325
Note payable	0	650
Debt, current portion	1,000	1,000
Total current liabilities	10,555	7,833
Debt, net of current portion	4,194	5,194
Total non-current liabilities	4,194	5,194
Total liabilities	14,749	13,027
Stockholders' equity (deficit):
Preferred stock, $0.001 par value; 10,000,000 authorized; no shares issued or outstanding as of June 30, 2023 and December 31, 2022	0	0
Common stock, $0.001 par value; 100,000,000 authorized; 2,612,038 and 34,761 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively	3	0
Additional paid-in capital	105,855	82,286
Accumulated deficit	(102,046)	(91,094)
Accumulated comprehensive income	990	759
Total stockholders' equity (deficit)	4,802	(8,049)
Total liabilities and stockholders' equity (deficit)	$ 19,551	$ 4,978

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	2,612,038	34,761
Common stock, shares outstanding (in shares)	2,612,038	34,761

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Operating expenses:
General and administrative	$ 1,643	$ 1,258	$ 2,995	$ 3,053
Research and development	4,234	20,028	7,750	22,236
Operating loss	(5,877)	(21,286)	(10,745)	(25,289)
Other income (expense):
Interest income	49	2	65	2
Interest expense	(70)	(16)	(173)	(20)
Other expense	(82)	(848)	(248)	(536)
Total other expense	(103)	(862)	(356)	(554)
Loss before income tax benefit	(5,980)	(22,148)	(11,101)	(25,843)
Income tax benefit	147	18	149	47
Net loss	(5,833)	(22,130)	(10,952)	(25,796)
Foreign currency translation adjustment	67	813	231	514
Comprehensive loss	$ (5,766)	$ (21,317)	$ (10,721)	$ (25,282)
Basic and diluted net loss per share (in dollars per share)	$ (7.95)	$ (1,843.68)	$ (22.08)	$ (2,243.10)
Weighted average shares outstanding - basic and diluted (in shares)	733,314	12,003	496,013	11,500

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' (Deficit) Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2021	10,995
Balances at Dec. 31, 2021	$ 0	$ 66,240	$ (56,160)	$ 133	$ 10,212
Stock-based compensation	0	334	0	0	334
Net loss	0	0	(3,666)	0	(3,666)
Foreign currency translation adjustment	$ 0	0	0	(299)	(299)
RSU's vested (in shares)	4
RSU's vested	$ 0	0	0	0	0
Balance (in shares) at Mar. 31, 2022	10,999
Balance at Mar. 31, 2022	$ 0	66,574	(59,826)	(166)	6,581
Balance (in shares) at Dec. 31, 2021	10,995
Balances at Dec. 31, 2021	$ 0	66,240	(56,160)	133	10,212
Net loss					(25,796)
Foreign currency translation adjustment					514
Balance (in shares) at Jun. 30, 2022	17,102
Balance at Jun. 30, 2022	$ 0	76,472	(81,956)	647	(4,838)
Balance (in shares) at Mar. 31, 2022	10,999
Balances at Mar. 31, 2022	$ 0	66,574	(59,826)	(166)	6,581
Stock-based compensation	0	293	0	0	293
Net loss	0	0	(22,130)	0	(22,130)
Foreign currency translation adjustment	$ 0	0	0	813	813
RSU's vested (in shares)	4
RSU's vested	$ 0	0	0	0	0
Issuance of common stock - CPP Acquisition (in shares)	6,099
Issuance of common stock - CPP Acquisition	$ 0	9,605	0	0	9,605
Balance (in shares) at Jun. 30, 2022	17,102
Balance at Jun. 30, 2022	$ 0	76,472	(81,956)	647	(4,838)
Balance (in shares) at Dec. 31, 2022	34,761
Balances at Dec. 31, 2022	$ 0	82,286	(91,094)	759	(8,049)
Proceeds from sale of Common Stock (in shares)	237,191
Proceeds from sale of Common Stock	$ 0	15,359	0	0	15,359
Cash paid for fractional shares	$ 0	(4)	0	0	(4)
Warrant exchange cashless (in shares)	264,124
Warrant exchange cashless	$ 1	(1)	0	0	0
Stock-based compensation	0	180	0	0	180
Net loss	0	0	(5,119)	0	(5,119)
Foreign currency translation adjustment	$ 0	0	0	164	164
Balance (in shares) at Mar. 31, 2023	536,076
Balance at Mar. 31, 2023	$ 1	97,820	(96,213)	923	2,531
Balance (in shares) at Dec. 31, 2022	34,761
Balances at Dec. 31, 2022	$ 0	82,286	(91,094)	759	(8,049)
Net loss					(10,952)
Foreign currency translation adjustment					231
Balance (in shares) at Jun. 30, 2023	2,612,038
Balance at Jun. 30, 2023	$ 3	105,855	(102,046)	990	4,802
Balance (in shares) at Mar. 31, 2023	536,076
Balances at Mar. 31, 2023	$ 1	97,820	(96,213)	923	2,531
Proceeds from sale of Common Stock (in shares)	2,008,881
Proceeds from sale of Common Stock	$ 2	7,711	0	0	7,713
Cash paid for fractional shares	$ 0	(5)	0	0	(5)
Warrant exchange cashless (in shares)	67,694
Warrant exchange cashless	$ 0	0	0	0	0
Stock-based compensation	0	329	0	0	329
Net loss	0	0	(5,833)	0	(5,833)
Foreign currency translation adjustment	$ 0	0	0	67	67
Adjustment for fractional shares (in shares)	(613)
Balance (in shares) at Jun. 30, 2023	2,612,038
Balance at Jun. 30, 2023	$ 3	$ 105,855	$ (102,046)	$ 990	$ 4,802

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities:
Net loss	$ (10,952)	$ (25,796)
Adjustments to reconcile net loss to net cash used in operating activities:
Write off of in process research and development (IPR&D)	0	17,737
Stock-based compensation	509	627
Non-cash interest expense	107	13
Changes in operating assets and liabilities:
Income tax receivable	(149)	(33)
Prepaid expenses and other current assets	(2,967)	(219)
Other non-current assets	(5,541)	(2,561)
Accounts payable	5,812	2,483
Accrued liabilities	(2,311)	(931)
Net cash used in operating activities	(15,492)	(8,680)
Cash flows from investing activities:
Investment in IPR&D	0	(659)
Cash acquired in merger	0	4
Net cash used in investing activities	0	(655)
Cash flows from financing activities:
Proceeds from sale of common stock and warrants, net of $2.1 million of offering costs	23,071	0
Cash paid for fractional shares	(9)	0
Principal payments on notes	(1,650)	0
Net cash provided by financing activities	21,412	0
Effect of exchange rate changes on cash	0	(2)
Net change in cash	5,920	(9,337)
Cash and cash equivalents at beginning of period	1,285	11,867
Cash and cash equivalents at end of period	7,205	2,530
Supplemental disclosure of cash flow information:
Cash paid during period for interest	386	7
Supplemental disclosure of non-cash transactions:
Fair value of common stock, stock options and stock warrants issued as consideration for asset acquisition	$ 0	$ 9,605

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals)	6 Months Ended
	Jun. 30, 2023 USD ($)
Proceeds from issuance of common stock and warrants, issuance costs	$ 2,100

Note 1 - Business

Note 1 - Business	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Business Panbela Therapeutics, Inc. (“Panbela”) and its direct wholly owned subsidiaries: Panbela Research, Inc. (“Panbela Research”) Cancer Prevention Pharmaceuticals, Inc. (“CPP”) and Cancer Prevention Pharma (Ireland) Limited exist for the primary purpose of developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. Panbela Therapeutics Pty Ltd is a wholly owned subsidiary of Panbela Research organized under the laws of Australia. Cancer Prevention has two The primary objective of our pipeline is the utilization of pharmacotherapies to reduce or normalize increased disease-associated polyamines using complementary pharmacotherapies. Our lead candidates are ivospemin (SBP- 101 1X 1X April 4, 2023. Reverse stock splits Effective June 1, 2023, 1 January 13, 2023, 1 7

Note 2 - Risks and Uncertaintie

Note 2 - Risks and Uncertainties	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Nature of Operations [Text Block]	2. Risks and Uncertainties The Company operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the Food and Drug Administration (the “FDA”) in the United States, the Therapeutic Goods Administration in Australia, the European Medicines Agency in the European Union, and comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may We have incurred losses of $102.0 million since our inception in 2011. six June 30, 2023 two June 30, 2023 The accompanying condensed consolidated financial statements have been prepared assuming that we will continue as a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The condensed not 2022 March 16, 2023. 4 In January 2022, not 19.

Note 3 - Basis of Presentation

Note 3 - Basis of Presentation	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	3. Basis of Presentation We have prepared the accompanying interim condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10 X not December 31. December 31, 2022, not 10 may not

Note 4 - Liquidity and Business

Note 4 - Liquidity and Business Plan	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	4. Liquidity and Business Plan On June 21, 2023, On January 30, 2023 first 2023 7 We need to raise additional capital to support our current business plans. We may no not Our future success is dependent upon our ability to obtain additional financing, the success of our development efforts, our ability to obtain marketing approval for our product candidates ivospemin, Flynpovi and eflornithine in the United States or other markets and ultimately our ability to market and sell product candidates. If we are unable to obtain additional financing when needed, if our clinical trials are not not There can be no

Note 5 - Summary of Significant

Note 5 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Significant Accounting Policies [Text Block]	5. Summary of Significant Accounting Policies Principles of consolidation The accompanying condensed consolidated financial statements include the assets, liabilities, and expenses of the Company. All significant intercompany transactions and balances have been eliminated in consolidation. Use of estimates The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates, particularly given the significant social and economic disruptions and uncertainties with the ongoing pandemic and control responses. Research and development costs Research and development costs include expenses incurred in the conduct of our clinical trials; for third We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are, and will be, performed at clinical trial sites and are administered jointly by us with assistance from contract research organizations (“CROs”). Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials generally are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual effort expended at each clinical trial site and by each CRO. The cost to secure certain third Research and development costs for 2022 All material CRO contracts are terminable by us upon written notice, and we are generally only liable for actual effort expended by the CROs and certain non-cancelable expenses incurred at any point of termination. We expense costs associated with obtaining licenses for patented technologies when it is determined there is no Stock-based compensation In accounting for stock-based incentive awards, we measure and recognize the cost of employee and non-employee services received in exchange for awards of equity instruments based on the fair value of those awards on the grant date. Calculating stock-based compensation expense requires the input of highly subjective assumptions, which represent our best estimates and involve inherent uncertainties and the application of management’s judgment. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. Compensation expense for performance-based stock option awards is recognized when “performance” has occurred or is probable of occurring. The fair value of stock-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of stock-based awards is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon U.S. Treasury rates appropriate for the expected term of each award. Expected volatility rates are based on historical company share price volatility. The assumed dividend yield is zero, as we do not Foreign currency translation adjustments The functional currency of Panbela Therapeutics Pty Ltd is the Australian Dollar. Accordingly, assets and liabilities, and equity transactions of Panbela Therapeutics Australia Pty Ltd, are translated into U.S. dollars at period-end exchange rates. Revenues and expenses are translated at the average exchange rate in effect for the period. The resulting translation gains and losses are recorded as a component of accumulated comprehensive loss presented within the stockholders’ equity. During the six June 30, 2023 2022, Comprehensive loss Comprehensive loss consists of our net loss and the effects of foreign currency translation. Net loss per share Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is based on the weighted average of common shares outstanding during the period plus dilutive potential common shares calculated using the treasury stock method. Such potentially dilutive shares are excluded when the effect is anti-dilutive or reduce a net loss per share. The Company’s potentially dilutive shares, which include outstanding common stock options, and warrants, have not The following table sets forth the potential shares of common stock that were not June 30, 2023 2022 Employee and non-employee stock options 13,455 3,367 Common stock issuable under common stock purchase warrants 4,832,926 4,539 4,846,381 7,906

Note 6 - Notes Payable

Note 6 - Notes Payable	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Debt Disclosure [Text Block]	6. Notes Payable Sucampo promissory note As of June 30, 2023, June 15, 2022. June 30, 2023 January 31, 2024, January 31, 2025, January 31, 2026; January 31, 2027. February 1, 2023, June 30, 2023, June 15, 2022. Tillotts promissory note As of December 31, 2022, January 31, 2023.

Note 7 - Stockholders' Equity

Note 7 - Stockholders' Equity	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Equity [Text Block]	7. Stockholders Equity Public offering of common stock and warrants June 2023 On June 21, 2023 June 30, 2023, 1. Of the remaining warrants, warrants to purchase 2,270,000 shares of common stock, have an alternative cashless exercise provision pursuant to which the holder may x June 28, 2023 June 30, 2023 August 4, 2023, As of August 4, 2023, Public offering of common stock and warrants January 2023 On January 30, 2023 1. All of the pre-funded warrants were exercised by February 3, 2023. may x March 1, 2023 June 30, 2023, At-the-market program We are party to a Sales Agreement dated July 29, 2022, may December 2022 During January 2023, No January, 2023. Reverse stock splits On May 25, 2023, one five 1:5 one one hundred 1:100 June 1, 2023, one thirty 1:30 thirty 30 one 1 No not June 1, 2023, one thirty 1:30 June 1, 2023. On November 29, 2022, one forty 1:40 January 13, 2023, forty 40 one 1 No not January 13, 2023, one forty 1:40 January 13, 2023. Shares reserved The following shares of common stock were reserved for future issuance as of the date indicated: June 30, 2023 Stock options outstanding 13,455 Shares available for grant under equity incentive plan - Warrants outstanding 4,832,926 4,846,381

Note 8 - Stock-based Compensati

Note 8 - Stock-based Compensation	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	8. Stock-based Compensation 2016 The Panbela Therapeutics, Inc. 2016 “2016 March 2016 May 2016. 2016 2016 no 2016 ten June 30, 2023, 2016 2011 Our Board of Directors ceased making awards under the Panbela Therapeutics, Inc. 2011 “2011 2016 May 2016. 2011 June 30, 2023, 2011 CPP s 2010 The Company has assumed all remaining rights and obligations with respect to CPP’s 2010 June 30, 2023, Stock-based compensation expense General and administrative (“G&A”) and research and development (“R&D”) expenses include non-cash stock-based compensation expense as a result of our issuance of stock options. The terms and vesting schedules for stock-based awards vary by type of grant and the employment status of the grantee. The awards granted through June 30, 2023 June 30, 2023. 15 Stock-based compensation expense for each of the periods presented is as follows (in thousands): Six Months Ended June 30, 2023 2022 General and Administrative $ 416 $ 507 Research and Development 93 120 $ 509 $ 627 Details of options available to grant, granted, exercised, cancelled, or forfeited during the six June 30, 2023 Shares Underlying Options Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Balance at January 1, 2023 3,287 $ 4,369 $ - Granted 10,240 15 Exercised - - Cancelled (72 ) 1,424 Forfeitures or expirations - - Balance at June 30, 2023 13,455 $ 1,071 $ - Information about stock options outstanding, vested and expected to vest as of June 30, 2023 Outstanding, Vested and Expected to Vest Options Vested and Exercisable Per Share Exercise Price Shares Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Options Exercisable Weighted Average Remaining Contractual Life (Years) $15.00 - $1,764.00 11,470 9.46 $ 52 2,892 8.62 $2,712.00 - $2,730.00 49 7.48 $ 2,714 18 6.23 $3,000.00 - $5,004.00 1,001 5.90 $ 4,081 897 5.68 $5,400.00 - $6,900.00 378 6.19 $ 6,247 378 6.19 $9,720.00 - $12,000.00 399 5.70 $ 10,955 355 5.53 $18,120.00 158 3.45 $ 18,120 158 3.45 Totals 13,455 8.92 $ 1,071 4,698 7.45 Assumptions used to calculate the fair market value of options granted in the six June 30, 2023 2023 Common stock fair value $15.00 Risk-free interest rate 3.59% - 3.60% Expected dividend yield - Expected Option life 5.08 - 5.50 Expected stock price volatility 131.3% - 138.0%

Note 9 - Subsequent Events

Note 9 - Subsequent Events	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Subsequent Events [Text Block]	9. Subsequent Events On July 17, 2023, not not not

Note 5 - Summary of Significa_2

Note 5 - Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2023
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	June 30, 2023 2022 Employee and non-employee stock options 13,455 3,367 Common stock issuable under common stock purchase warrants 4,832,926 4,539 4,846,381 7,906

Note 7 - Stockholders' Equity (

Note 7 - Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2023
Notes Tables
Schedule of Common Stock Reserved for Future Issuance [Table Text Block]	June 30, 2023 Stock options outstanding 13,455 Shares available for grant under equity incentive plan - Warrants outstanding 4,832,926 4,846,381

Note 8 - Stock-based Compensa_2

Note 8 - Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2023
Notes Tables
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Six Months Ended June 30, 2023 2022 General and Administrative $ 416 $ 507 Research and Development 93 120 $ 509 $ 627
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Shares Underlying Options Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Balance at January 1, 2023 3,287 $ 4,369 $ - Granted 10,240 15 Exercised - - Cancelled (72 ) 1,424 Forfeitures or expirations - - Balance at June 30, 2023 13,455 $ 1,071 $ -
Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Outstanding, Vested and Expected to Vest Options Vested and Exercisable Per Share Exercise Price Shares Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Options Exercisable Weighted Average Remaining Contractual Life (Years) $15.00 - $1,764.00 11,470 9.46 $ 52 2,892 8.62 $2,712.00 - $2,730.00 49 7.48 $ 2,714 18 6.23 $3,000.00 - $5,004.00 1,001 5.90 $ 4,081 897 5.68 $5,400.00 - $6,900.00 378 6.19 $ 6,247 378 6.19 $9,720.00 - $12,000.00 399 5.70 $ 10,955 355 5.53 $18,120.00 158 3.45 $ 18,120 158 3.45 Totals 13,455 8.92 $ 1,071 4,698 7.45
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2023 Common stock fair value $15.00 Risk-free interest rate 3.59% - 3.60% Expected dividend yield - Expected Option life 5.08 - 5.50 Expected stock price volatility 131.3% - 138.0%

Note 1 - Business (Details Text

Note 1 - Business (Details Textual)	Jun. 01, 2023	Jan. 13, 2023
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	30	40

Note 2 - Risks and Uncertaint_2

Note 2 - Risks and Uncertainties (Details Textual) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Retained Earnings (Accumulated Deficit)	$ (102,046)				$ (102,046)		$ (91,094)
Net Income (Loss) Attributable to Parent	(5,833)	$ (5,119)	$ (22,130)	$ (3,666)	(10,952)	$ (25,796)
Net Cash Provided by (Used in) Operating Activities					(15,492)	(8,680)
Net Cash Provided by (Used in) Financing Activities					21,412	0
Cash and Cash Equivalents, at Carrying Value	7,205				7,205		1,285
Working Capital	300				300
Equity, Attributable to Parent	$ 4,802	$ 2,531	$ (4,838)	$ 6,581	$ 4,802	$ (4,838)	$ (8,049)	$ 10,212

Note 4 - Liquidity and Busine_2

Note 4 - Liquidity and Business Plan (Details Textual) - USD ($) $ in Millions			1 Months Ended	6 Months Ended
	Jun. 21, 2023	Jan. 30, 2023	Jan. 30, 2023	Jun. 30, 2023
Registered Public Offering [Member]
Proceeds from Issuance or Sale of Equity	$ 7.7	$ 13.8
ATM Program [Member]
Proceeds from Issuance of Common Stock			$ 1.6	$ 1.6

Note 5 - Summary of Significa_3

Note 5 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Anti-dilutive securities (in shares)	4,846,381	7,906
Share-Based Payment Arrangement [Member]
Anti-dilutive securities (in shares)	13,455	3,367
Warrant [Member]
Anti-dilutive securities (in shares)	4,832,926	4,539

Note 6 - Notes Payable (Details

Note 6 - Notes Payable (Details Textual) - USD ($)	Feb. 01, 2023	Jun. 15, 2022	Jun. 30, 2023	Dec. 31, 2022
Sucampo Note [Member]
Long-Term Debt			$ 5,300,000
Debt Instrument, Face Amount		$ 6,200,000
Long-Term Debt, Gross			5,200,000
Debt Instrument, Interest Rate, Stated Percentage		5%
Debt Instrument, Periodic Payment, Total		$ 1,000,000
Repayments of Long-Term Debt	$ 1,000,000
Interest Paid, Including Capitalized Interest, Operating and Investing Activities	$ 295,000
Interest Payable			$ 106,700
Tillotts Note [Member]
Long-Term Debt				$ 700,000
Debt Instrument, Face Amount				$ 650,000

Note 7 - Stockholders' Equity_2

Note 7 - Stockholders' Equity (Details Textual)							1 Months Ended	6 Months Ended	12 Months Ended
	Aug. 04, 2023 $ / shares shares	Jun. 21, 2023 USD ($) $ / shares shares	Jun. 01, 2023	May 25, 2023	Jan. 30, 2023 USD ($) $ / shares shares	Jan. 13, 2023	Jan. 30, 2023 USD ($) $ / shares shares	Jun. 30, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($)	Jul. 29, 2022 USD ($)
Payments of Stock Issuance Costs | $								$ 2,100
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio			30			40
Reverse Stock Split [Member] | Minimum [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio				5
Reverse Stock Split [Member] | Maximum [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio				100
Pre-funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		1,684,000			61,090		61,090
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 0.001			$ 0.001		$ 0.001
Prefunded Warrants Exercised Shares (in shares)		261,000
Common Stock Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		4,540,000			445,000		445,000	2,566
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 3.75			$ 82.50		$ 82.50	$ 82.50
Class of Warrants or Rights, Eligible for Cashless Exercise (in shares)		2,270,000
Class of Warrants or Rights, Cashless Exchange Feature (in shares)		0.24			0.75		0.75
Class of Warrant or Right, Exercised During Period (in shares)	353,100							442,433
Stock Issued During Period, Shares, Warrants Exercised (in shares)								331,824
Common Stock Warrants [Member] | Subsequent Event [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	4,186,900
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 3.75
Class of Warrants or Rights, Eligible for Cashless Exercise (in shares)	1,916,900
Stock Issued During Period, Shares, Cashless Exercise of Warrants (in shares)	84,744
Registered Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)		586,000			161,407
Units Issued, Stock and Warrant, Price Per Share (in dollars per share) | $ / shares		$ 3.75			$ 67.50		$ 67.50
Units Issued, Stock and Warrant, Number of Warrants Per Unit (in shares)		2			2		2
Units Issued, Warrant and Warrant, Price Per Unit (in dollars per share) | $ / shares		$ 3.749			$ 67.47		$ 67.47
Units Issued, Warrant and Warrant, Warrant Per Unit (in shares)		2			2		2
Proceeds from Issuance or Sale of Equity | $		$ 7,700,000			$ 13,800,000
Stock Issued During Period, Shares, Cashless Exercise of Warrants (in shares)								0
ATM Program [Member]
Stock Issued During Period, Shares, New Issues (in shares)							14,694
Equity Offering, Maximum Amount | $										$ 8,400,000
Equity Offering, Commission, Percentage of Gross Proceeds									3%
Payments of Stock Issuance Costs | $									$ 44,000
Proceeds from Issuance of Common Stock | $							$ 1,600,000	$ 1,600,000

Note 7 - Stockholders' Equity -

Note 7 - Stockholders' Equity - Common Stock Reserved for Future Issuance (Details)	Jun. 30, 2023 shares
Shares reserved (in shares)	4,846,381
Warrant [Member]
Shares reserved (in shares)	4,832,926
Share-Based Payment Arrangement, Option [Member]
Shares reserved (in shares)	13,455
Shares Available for Grant Under Equity Incentive Plan [Member]
Shares reserved (in shares)	0

Note 8 - Stock-based Compensa_3

Note 8 - Stock-based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Millions	6 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	13,455	3,287
Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 1,071
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 0.4
Panbela Therapeutics, Inc. 2016 Omnibus Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)	12,054
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)	9 years 2 months 12 days
Panbela Therapeutics, Inc. 2011 Stock Option Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)	171
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)	1 year 7 months 6 days
CPP's 2010 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)	1,230
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)	7 years 1 month 6 days
Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 361.56

Note 8 - Stock-based Compensa_4

Note 8 - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Share-based compensation expense	$ 509	$ 627
General and Administrative Expense [Member]
Share-based compensation expense	416	507
Research and Development Expense [Member]
Share-based compensation expense	$ 93	$ 120

Note 8 - Stock-based Compensa_5

Note 8 - Stock-based Compensation - Summary of Option Activity (Details)	6 Months Ended
	Jun. 30, 2023 USD ($) $ / shares shares
Balance, shares available for grant (in shares)	3,287
Balance, weighted average exercise price per share (in dollars per share) | $ / shares	$ 4,369
Aggregate intrinsic value | $	$ 0
Granted, shares available for grant (in shares)	10,240
Granted, weighted average exercise price per share (in dollars per share) | $ / shares	$ 15
Excercised, shares available for grant (in shares)	0
Cancelled, shares available for grant (in shares)	(72)
Cancelled, weighted average exercise price per share (in dollars per share) | $ / shares	$ 1,424
Forfeitures or expirations (in shares)	0
Forfeitures or expirations (in dollars per share) | $ / shares	$ 0
Balance, shares available for grant (in shares)	13,455
Balance, weighted average exercise price per share (in dollars per share) | $ / shares	$ 1,071

Note 8 - Stock-based Compensa_6

Note 8 - Stock-based Compensation - Options Outstanding (Details)	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Options outstanding (in shares) | shares	13,455
Options outstanding, weighted average remaining contractual life (Year)	8 years 11 months 1 day
Options outstanding, weighted average exercise price (in dollars per share)	$ 1,071
Options exercisable (in shares) | shares	4,698
Options excercisable, weighted average remaining contractual life (Year)	7 years 5 months 12 days
Exercise Price Range 1 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 15
Per share exercise price, upper limit (in dollars per share)	$ 1,764
Options outstanding (in shares) | shares	11,470
Options outstanding, weighted average remaining contractual life (Year)	9 years 5 months 15 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 52
Options exercisable (in shares) | shares	2,892
Options excercisable, weighted average remaining contractual life (Year)	8 years 7 months 13 days
Exercise Price Range 2 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 2,712
Per share exercise price, upper limit (in dollars per share)	$ 2,730
Options outstanding (in shares) | shares	49
Options outstanding, weighted average remaining contractual life (Year)	7 years 5 months 23 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 2,714
Options exercisable (in shares) | shares	18
Options excercisable, weighted average remaining contractual life (Year)	6 years 2 months 23 days
Exercise Price Range 3 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 3,000
Per share exercise price, upper limit (in dollars per share)	$ 5,004
Options outstanding (in shares) | shares	1,001
Options outstanding, weighted average remaining contractual life (Year)	5 years 10 months 24 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 4,081
Options exercisable (in shares) | shares	897
Options excercisable, weighted average remaining contractual life (Year)	5 years 8 months 4 days
Exercise Price Range 4 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 5,400
Per share exercise price, upper limit (in dollars per share)	$ 6,900
Options outstanding (in shares) | shares	378
Options outstanding, weighted average remaining contractual life (Year)	6 years 2 months 8 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 6,247
Options exercisable (in shares) | shares	378
Options excercisable, weighted average remaining contractual life (Year)	6 years 2 months 8 days
Exercise Price Range 5 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 9,720
Per share exercise price, upper limit (in dollars per share)	$ 12,000
Options outstanding (in shares) | shares	399
Options outstanding, weighted average remaining contractual life (Year)	5 years 8 months 12 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 10,955
Options exercisable (in shares) | shares	355
Options excercisable, weighted average remaining contractual life (Year)	5 years 6 months 10 days
Exercise Price Range 6 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 18,120
Options outstanding (in shares) | shares	158
Options outstanding, weighted average remaining contractual life (Year)	3 years 5 months 12 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 18,120
Options exercisable (in shares) | shares	158
Options excercisable, weighted average remaining contractual life (Year)	3 years 5 months 12 days

Note 8 - Stock-based Compensa_7

Note 8 - Stock-based Compensation - Fair Market Value Assumptions of Options Granted (Details)	6 Months Ended
	Jun. 30, 2023 USD ($) $ / shares
Common stock fair value (in dollars per share) | $ / shares	$ 15
Expected dividend yield | $	$ 0
Minimum [Member]
Risk-free interest rate	3.59%
Expected Option life (Year)	5 years 29 days
Expected stock price volatility	131.30%
Maximum [Member]
Risk-free interest rate	3.60%
Expected Option life (Year)	5 years 6 months
Expected stock price volatility	138%

Note 9 - Subsequent Events (Det

Note 9 - Subsequent Events (Details Textual) - Subsequent Event [Member]	Jul. 17, 2023 USD ($)
Proceeds from Divestiture of Businesses and Interests in Affiliates	$ 400,000
Maximum [Member]
Disposal Group, Including Discontinued Operation, Consideration	$ 9,500,000